Merck to invest $1B in US plant to make cancer – Business News
Drugmaker Merck mentioned Tuesday it’s investing $1 billion in a new Delaware plant to develop home manufacturing because it prepares to deal with President Trump’s tariffs.
The new facility will produce biologic medication and Keytruda, turning into Merck’s first in-house US website to make the blockbuster cancer therapy, the company mentioned.
Merck mentioned final week its greatest tariff publicity is thru Keytruda and it has enough US stock for this yr. It estimated $200 million in further prices for the levies carried out to date.
The new facility will produce biologic medication and Keytruda, turning into Merck’s first in-house US website to make the blockbuster cancer therapy, the company mentioned. REUTERS
The company expects labs on the new facility to be totally operational by 2028 and produce experimental medication by 2030.
The new plant would create no less than 500 full-time jobs and about 4,000 construction vacancies, the company mentioned.
Merck opened a $1 billion facility at its North Carolina website final month to increase US manufacturing.
The Trump administration has been placing strain on US drugmakers to transfer their medication manufacturing to the nation and introduced probes into drug imports that set the stage for levies in the sector.
Merck mentioned final week its greatest tariff publicity is thru Keytruda and it has enough US stock for this yr. REUTERS
US drugmakers, together with Eli Lilly and Johnson & Johnson, have just lately introduced further investments to increase home manufacturing amid the tariff menace.
